{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"ProMIS Neurosciences Inc."},"Symbol":{"label":"Symbol","value":"PMN"},"Address":{"label":"Address","value":"Canada"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It primarily operates in Canada."},"CompanyUrl":{"label":"Company Url","value":"https://www.promisneurosciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Gavin T. Malenfant","title":"Chief Operating Officer"},{"name":"Larry Douglas Altstiel","title":"Chief Medical Officer"},{"name":"Neil K. Warma","title":"President, Chief Executive Officer & Director"},{"name":"Neil R. Cashman","title":"Director & Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}